AJJ MEDTECH HOLDINGS LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 198403368H)

COMPLETION OF THE PROPOSED PLACEMENT OF AN AGGREGATE OF 150,227,273 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY

---

1. INTRODUCTION

The Board of Directors (the "**Board**" or the "**Directors**") of AJJ Medtech Holdings Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 25 September 2026 (the "**Previous Announcement**") and 29 October 2026 in relation to the proposed placement of an aggregate of 150,227,273 new ordinary shares (the "**Placement Shares**") at an issue price of S$0.0044 (the "**Placement Price**") to several investors (the "**Placees**").

Unless otherwise defined herein, all capitalised terms used herein shall have the meanings ascribed to them in the Previous Announcement.

2. COMPLETION OF THE PLACEMENT

The Board wishes to announce that in accordance with the terms and conditions of the Placement Agreement, the Company has received the aggregate Placement Price of S$661,000 from the Placees. Accordingly, the Company has on 29 October 2026 allotted and issued an aggregate of 150,227,273 Placement Shares to the Placees ("**Completion**") as follows:

(a) 13,636,364 Placement Shares to Guo Wenqun;

(b) 71,818,182 Placement Shares to Chua June Gay;

(c) 37,500,000 Placement Shares to Huang Qiang;

(d) 15,909,091 Placement Shares to Ng Wei Jie; and

(e) 11,363,636 Placement Shares to Zhao Xin.

Following Completion, the total number of issued and paid-up ordinary shares of the Company has increased from 1,731,538,300 Shares to 1,881,765,573 Shares. The Placement Shares shall rank *pari passu* in all respects with and carry all rights similar to existing Shares as at the date of Completion, except that the Placement Shares shall not rank for any dividend, right, allotment or other distributions, the Record Date of which falls on or before the date of Completion.

The Placement Shares are expected to be listed and quoted on the Catalist board of the SGX-ST with effect from 9.00 a.m. on 30 October 2026.

By Order of the Board

Dr. Tan Wei Jie
Chief Executive Officer and Executive Director

29 October 2026

---

*This document has been reviewed by the Company's sponsor, Evolve Capital Advisory Private Limited (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Mr. Jerry Chua (Tel: (65) 6241 6626), at 160 Robinson Road, #20-01/02, SBF Centre, Singapore 068914.